Monday, April 24, 2017 7:05:35 PM
Let's just say we were fully diluted at 260 million shares outstanding.
Five billion / 250 million = 20 PPS (Note: 300 million fully diluted would = 16.67)
Five billion is the price some 'round here balked at 20 months ago. I think Five billion is very low if DCVax-l succeeds.
Ten billion / 250 million = 40 pps
Twenty billion = 80 pps This is about the price range Larry thinks the stock could run to if successful with the DCVax-L trial .
The company's potential value should be based upon far more than DCVax-L as a monotherapy for various indications. It should take into account DCVax-Direct. Combinations with Direct and L, and potential licensing.
I could care less what bears think right now. The shorts won the price per share battle. They helped India win the race to commercialization. Congrats. Shorts are very very rich. The question is, can the science come through.
Pyrr's unsubstantiated claims of certainty do not change the science. No one on the outside objectively knows what is going to happen.
Five billion / 250 million = 20 PPS (Note: 300 million fully diluted would = 16.67)
Five billion is the price some 'round here balked at 20 months ago. I think Five billion is very low if DCVax-l succeeds.
Ten billion / 250 million = 40 pps
Twenty billion = 80 pps This is about the price range Larry thinks the stock could run to if successful with the DCVax-L trial .
The company's potential value should be based upon far more than DCVax-L as a monotherapy for various indications. It should take into account DCVax-Direct. Combinations with Direct and L, and potential licensing.
I could care less what bears think right now. The shorts won the price per share battle. They helped India win the race to commercialization. Congrats. Shorts are very very rich. The question is, can the science come through.
Pyrr's unsubstantiated claims of certainty do not change the science. No one on the outside objectively knows what is going to happen.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
